Tag: Hematology

The US Food and Drug Administration (FDA) has approved brexucabtagene autoleucel (Tecartus) for the treatment of adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The therapy is the first chimeric antigen receptor (CAR) T-cell treatment approved for adults with ALL. This is a “meaningful advance,” because “roughly

A personalized genomic cancer vaccine proved feasible to manufacture and was well tolerated in a phase 1 trial, according to researchers. The vaccine, PGV-001, was given to 13 patients with solid tumors or multiple myeloma who had a high risk of recurrence after surgery or autologous stem cell transplant. At last follow-up, four patients were

Factor V Leiden is not a disease, but a genetic mutation that results in thrombophilia, a blood clotting condition that increases a person’s risk of developing abnormal blood clots in their blood vessels. People with factor V Leiden are at an increased risk of deep vein thrombosis (DVT), or a pulmonary embolism (PE), but some